Company Analysis
Sign in

ProKidney Corp. (PROK)

Nasdaq: PROK · Biological Products, (No Diagnostic Substances) · Winston-Salem, NC · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.3
◀ Past 5.6● Present 3.6▶ Future 6.5
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ProKidney Corp.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 2 in 2024 and none in 2023
Applications published
9
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ProKidney its own name
named as the applicant on its applications, in KY
0 granted
9 published
PROKIDNEY its own name
KY, as the owner printed on each patent
7 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,447,179Compositions comprising cell-delivered vesicles and uses thereofPharmaceuticalsPROKIDNEY
Sep 9, 202512,409,191Renal cell populations and uses thereofPharmaceuticalsPROKIDNEY
Jul 8, 202512,350,292Bioactive renal cells for the treatment of chronic kidney diseasePharmaceuticalsPROKIDNEY
Dec 3, 202412,157,887Bioactive renal cellsBiotechnologyPROKIDNEY
Mar 19, 202411,931,383Bioactive renal cells for the treatment of chronic kidney diseasePharmaceuticalsPROKIDNEY
Jun 28, 202211,369,639Renal cell populations and uses thereofPharmaceuticalsPROKIDNEY
Sep 21, 202111,123,372Bioactive renal cells for the treatment of chronic kidney diseasePharmaceuticalsPROKIDNEY
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367238SELECTED RENAL CELL POPULATIONS, CHARACTERISTICS AND USES THEREOFBiotechnologyProKidney
Sep 18, 20252025/0288616BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASEPharmaceuticalsProKidney
May 15, 20252025/0152632RENAL CELL POPULATIONS AND USES THEREOFPharmaceuticalsProKidney
Dec 12, 20242024/0409941BIOACTIVE RENAL CELLSBiotechnologyProKidney
Sep 26, 20242024/0316108BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASEPharmaceuticalsProKidney · patent 12,350,292 granted from it
Apr 4, 20242024/0108657ISOLATED RENAL CELLS AND USES THEREOFPharmaceuticalsProKidney
Nov 3, 20222022/0347221RENAL CELL POPULATIONS AND USES THEREOFPharmaceuticalsProKidney · patent 12,409,191 granted from it
Aug 11, 20222022/0249569ORGANOIDS COMPRISING ISOLATED RENAL CELLS AND USES THEREOFPharmaceuticalsProKidney
Feb 3, 20222022/0031755BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASEPharmaceuticalsProKidney · patent 11,931,383 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PROK · research, not advice